Cited by 170Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and LipoproteinsLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Cohn, Jeffrey S., Patterson, Bruce W., Uffelman, Kris D., Davignon, Jean, Steiner, George·2004·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jc.2003-032056

Open this paper in CoChat — free account

Abstract

Overweight individuals with reduced insulin sensitivity often have mild to moderate hypertriglyceridemia. To investigate the role of apolipoprotein (apo)C-III metabolism in the etiology of hypertriglyceridemia in these individuals, we investigated 10 male subjects with different body weights (body mass index, 24-34 kg/m(2)) and insulin sensitivity (homeostasis model assessment, 4.7-35.0). Total plasma and very-low-density lipoprotein (VLDL) apoC-III kinetics, as well as VLDL triglyceride (TG) and VLDL apoB kinetics, were measured with iv injected stable isotopes. The apoC-III, TG, and apoB levels in VLDL ranged from 2.9-18.2 mg/dl, 0.49-2.89 mmol/liter, and 6.7-29.3 mg/dl, respectively. Mean production rates (PRs) were: VLDL apoC-III, 20.2 +/- 4.1 micromol/d (range, 8.0-44.8); VLDL TG, 26.9 +/- 4.6 mmol/d (range, 10.2-51.1); and VLDL apoB, 4.4 +/- 0.8 micromol/d (range, 1.5-9.1). VLDL apoC-III PRs were significantly correlated with body mass index, homeostasis model assessment, and plasma TG (r = 0.66, P < 0.05; r = 0.80, P < 0.01; r = 0.95, P < 0.001, respectively). Similar correlations were found for plasma apoC-III PRs (r = 0.70, P < 0.05; r = 0.67, P < 0.05; r = 0.80, P < 0.01, respectively). Fractional catabolic rates (FCRs) were not significantly related to metabolic variables. VLDL TG levels were strongly related to VLDL apoC-III levels (r = 0.99, P < 0.001) and VLDL apoC-III PRs (r = 0.94, P < 0.001). VLDL apoC-III levels were more strongly correlated with VLDL TG PRs (r = 0.81, P < 0.01) than with VLDL TG FCRs or VLDL apoB FCRs (r = -0.53, P = 0.12; r = -0.37, P = 0.29). These results suggest that increased hepatic production of VLDL apoC-III is characteristic of subjects with higher body weights and lower levels of insulin sensitivity and is strongly related to the plasma concentration and level of production of VLDL TG.

Integrity signals

Registry

Crossref · 10.1210/jc.2003-032056

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,372
Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes
Lewis, G. F., Carpentier, A. C., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,370
Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., & Breslow, J. L. (1990) · Science · doi:10.1126/science.2167514 · Cited by 539
Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3
Jong, M. C., Hofker, M. H., & Havekes, L. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.472 · Cited by 539
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Brown, W. V., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 493
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
Aalto‐Setälä, K., Fisher, E. A. A., Chen, X., Chajek‐Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 453
Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources
Havel, R. J., Fielding, C. J., Olivecrona, T., Shore, V. G., Fielding, P. E., & Egelrud, T. (1973) · Biochemistry · doi:10.1021/bi00733a026 · Cited by 332
Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals
Lewis, G. F., Uffelman, K. D., Szeto, L., & Steiner, G. A. (1993) · Diabetes · doi:10.2337/diab.42.6.833 · Cited by 323
Self-citation
Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver.
Windler, E. E. T., & Havel, R. J. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34342-x · Cited by 314

Show all 58 references

Sorted by citations

Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
“The increase in triglyceride production may be due to excess free fatty acids returning to the liver, particularly in the setting of visceral obesity and insulin resistance, and increased de novo triglyceride production due to hyperinsulinemia (24, 62, 63).”
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418
Fat Depots, Free Fatty Acids, and Dyslipidemia
Ebbert, J. O., & Jensen, M. D. (2013) · Nutrients · doi:10.3390/nu5020498 · Cited by 355
Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease: Role of High-Density Lipoprotein–Proteome Remodeling
Riwanto, M., Rohrer, L., Roschitzki, B., Besler, C., Mocharla, P., Mueller, M., Perisa, D., Heinrich, K., Altwegg, L., von Eckardstein, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.108753 · Cited by 337
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Causes and consequences of hypertriglyceridemia
Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239
Diabetic Dyslipidemia
Chahil, T. J., & Ginsberg, H. N. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.002 · Cited by 233
Genetically engineered pigs as models for human disease
Perleberg, C., Kind, A., & Schnieke, A. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.030783 · Cited by 222
Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia
Sparks, J. D., Sparks, C. E., & Adeli, K. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241463 · Cited by 247
Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223
Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells
Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0159-y · Cited by 193
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
Fisher, E. A. A., & Cohen, D. E. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358519 · Cited by 189
Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia
Deeg, M. A., Buse, J. B., Goldberg, R. B., Kendall, D. M., Zagar, A. J., Jacober, S. J., Khan, M. A., Perez, A. T., Tan, M. H., & on behalf of the GLAI Study Investigators (2007) · Diabetes Care · doi:10.2337/dc06-1903 · Cited by 180
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions
Sundaram, M., Zhong, S., Khalil, M. B., Links, P. H., Zhao, Y., Iqbal, J., Hussain, M. M., Parks, R. J., Wang, Y., & Yao, Z. (2009) · Journal of Lipid Research · doi:10.1194/m900346-jlr200 · Cited by 176
The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia
Sacks, F. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000146 · Cited by 168
Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Self-citation
Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia
Caron, S., Verrijken, A., Mertens, I. L., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., et al. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.220723 · Cited by 168
Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects
Taskinen, M.-R., Adiels, M., Westerbacka, J., Söderlund, S., Kahri, J., Lundbom, N., Lundbom, J., Hakkarainen, A., Olofsson, S.-O., Orho-Melander, M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.224808 · Cited by 153
Hypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152
Role of triglyceride-rich lipoproteins in diabetic nephropathy
Rutledge, J. C., Ng, K. F., Aung, H. H., & Wilson, D. W. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.59 · Cited by 152
ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan
Hiukka, A., Ståhlman, M., Pettersson, C., Levin, M. C., Adiels, M., Teneberg, S., Leinonen, E. S., Hultén, L. M., Wiklund, O., Orešič, M., et al. (2009) · Diabetes · doi:10.2337/db09-0206 · Cited by 141
The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis
Wyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance
Lee, H., Birkenfeld, A. L., Jornayvaz, F. R., Jurczak, M. J., Kanda, S., Popov, V., Frederick, D. W., Zhang, D., Guigni, B. A., Bharadwaj, K. G., et al. (2011) · Hepatology · doi:10.1002/hep.24571 · Cited by 135
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 131
Lipotoxicity as a trigger factor of renal disease
Izquierdo-Lahuerta, A., Martínez-García, C., & Medina-Gómez, G. (2016) · JN. Journal of Nephrology (Milano. 1992) · doi:10.1007/s40620-016-0278-5 · Cited by 110
Lipids and lipid management in diabetes
Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 118
Apolipoprotein C-III
Kohan, A. B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000136 · Cited by 116
Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL)
Huang, J.-K., & Lee, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084300 · Cited by 115
Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100
Apolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98
Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes
Hiukka, A., Fruchart‐Najib, J., Leinonen, E. S., Hilden, H., Fruchart, J., & Taskinen, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1753-z · Cited by 96
Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95
Apolipoprotein CIII Links Hyperlipidemia With Vascular Endothelial Cell Dysfunction
Kawakami, A., Osaka, M., Tani, M., Azuma, H., Sacks, F. M., Shimokado, K., & Yoshida, M. (2008) · Circulation · doi:10.1161/circulationaha.108.784785 · Cited by 92
Retracted
Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
Keirns, B. H., Sciarrillo, C. M., Koemel, N. A., & Emerson, S. R. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.73 · Cited by 86
Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70
Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70
Effects of bariatric surgery on lipid-lipoprotein profile
Piché, M., Tardif, I., Auclair, A., & Poirier, P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154441 · Cited by 72
Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII
Li, H., Han, Y., Qi, R., Wang, Y., Zhang, X., Yu, M., Tang, Y., Wang, M., Shu, Y.-N., Huang, W. Y., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv192 · Cited by 64
Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000199815.46720.ca · Cited by 65
Untitled work
Ginsberg (2011) · doi:10.1161/atvbaha.110.221846 · Cited by 64
Genetically modified pigs to model human diseases
Flisikowska, T., Kind, A., & Schnieke, A. (2013) · Journal of Applied Genetics · doi:10.1007/s13353-013-0182-9 · Cited by 63
New Therapies for Lowering Triglyceride-Rich Lipoproteins
Rosenson, R. S., Shaik, A., & Song, W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.051 · Cited by 68
Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease
Ooi, E. M. M., Chan, D. T., Watts, G. F., Chan, D. C., Ng, T. W., Dogra, G. K., Irish, A. B., & Barrett, P. H. R. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011163 · Cited by 66
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia
Cohn, J. S., Tremblay, M., Batal, R., Jacques, H., Rodriguez, C., Steiner, G. A., Mamer, O., & Davignon, J. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.06.011 · Cited by 62
Self-citation
Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism
Chan, D. C., Nguyen, M. N., Watts, G. F., & Barrett, P. H. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2676 · Cited by 63
Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia
Sundaram, M., Zhong, S., Khalil, M. B., Zhou, H., Jiang, Z. G., Zhao, Y., Iqbal, J., Hussain, M. M., Figeys, D., Wang, Y., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005108 · Cited by 58
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813942 · Cited by 58
The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients
Majali, K. A., Cooper, M. B., Staels, B., Luc, G., Taskinen, M., & Betteridge, D. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0092-4 · Cited by 58
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
Intrahepatic Role of Exchangeable Apolipoproteins in Lipoprotein Assembly and Secretion
Sundaram, M., & Yao, Z. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241455 · Cited by 62
Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes
Koška, J., Yassine, H. N., Trenchevska, O., Sinari, S. A., Schwenke, D. C., Yen, F. T., Billheimer, D. D., Nelson, R. W., Nedelkov, D., & Reaven, P. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p064816 · Cited by 56
Management of Hypertriglyceridemia
Labossiere, R., & Goldberg, I. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_10 · Cited by 54
Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Khavandi, M., Duarte, F., Ginsberg, H. N., & Reyes‐Soffer, G. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0818-1 · Cited by 58
Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease
Hyysalo, J., Stojkovic, I., Kotronen, A., Hakkarainen, A., Sevastianova, K., Makkonen, J., Lundbom, N. M. I., Rissanen, A., Krauss, R. M., Melander, O., et al. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07045.x · Cited by 55
ApoCIII: A multifaceted protein in cardiometabolic disease
D’Erasmo, L., Costanzo, A. D., Gallo, A., Bruckert, É., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 52
Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism
Mauger, J., Couture, P., Bergeron, N., & Lamarche, B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m500455-jlr200 · Cited by 51
Triglyceride-Rich Lipoprotein-Associated Apolipoprotein C-III Production Is Stimulated by Plasma Free Fatty Acids in Humans
Pavlic, M., Valéro, R., Duez, H., Xiao, C., Szeto, L., Patterson, B. W., & Lewis, G. F. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.169383 · Cited by 53
Self-citation
Proteomic analysis of human very low‐density lipoprotein by two‐dimensional gel electrophoresis and MALDI‐TOF/TOF
Mancone, C., Amicone, L., Fimia, G. M., Bravo, E., Piacentini, M., Tripodi, M., & Alonzi, T. (2006) · PROTEOMICS · doi:10.1002/pmic.200600339 · Cited by 51
Apolipoprotein CIII and Atherosclerosis
Bobik, A. (2008) · Circulation · doi:10.1161/circulationaha.108.794081 · Cited by 53
Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII
Wei, J., Ouyang, H., Wang, Y., Pang, D., Cong, N., Wang, T., Leng, B., Li, D., Li, X., Wu, R., et al. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08401.x · Cited by 54
Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., & Stalenhoef, A. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.002 · Cited by 50
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies
Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.02.008 · Cited by 47
Large triglyceride-rich lipoproteins in hypertriglyceridemia are associated with the severity of acute pancreatitis in experimental mice
Zhang, Y., He, W., He, C., Wan, J., Lin, X., Zheng, X., Li, L., Li, X., Yang, X., Yu, B., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1969-3 · Cited by 47
ApoE ε2/ε3/ε4 polymorphism, ApoC-III/ApoE ratio and metabolic syndrome
Olivieri, O., Martinelli, N., Bassi, A., Trabetti, E., Girelli, D., Pizzolo, F., Friso, S., Pignatti, P. F., & Corrocher, R. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0142-y · Cited by 46
The physiology of MASLD: molecular pathways between liver and adipose tissues
Lee, W., Kipp, Z. A., Bates, E. A., Pauss, S. N., Martinez, G. J., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20257571 · Cited by 52
Effects of Bariatric Surgery on Hepatic and Intestinal Lipoprotein Particle Metabolism in Obese, Nondiabetic Humans
Padilla, N., Maraninchi, M., Béliard, S., Berthet, B., Nogueira, J. P., Wolff, E., Nicolay, A., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303849 · Cited by 44
Dose-Dependent Effect of Rosuvastatin on VLDL–Apolipoprotein C-III Kinetics in the Metabolic Syndrome
Ooi, E. M. M., Watts, G. F., Chan, D. C., Chen, M., Nestel, P. J., Sviridov, D., & Barrett, P. H. R. (2008) · Diabetes Care · doi:10.2337/dc08-0358 · Cited by 41
Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits
Yan, H., Niimi, M., Matsuhisa, F., Zhou, H., Kitajima, S., Chen, Y., Wang, C., Yang, X., Yao, J. Q., Yang, D., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314368 · Cited by 39
Lipid accumulation product (LAP) as a potential index to predict risk of insulin resistance in young, non-obese Asian Indian males from Southern India: observations from hyperinsulinemic-euglycemic clamp studies
Shajith Anoop, S., Dasgupta, R., Rebekah, G. J., Jose, A., Inbakumari, M., Geethanjali, F. S., & Thomas, N. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002414 · Cited by 41
High-density lipoprotein and transport of cholesterol and triglyceride in blood
Brown, W. V. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.02.001 · Cited by 42
Relationship between serum adiponectin level and lipid composition in each lipoprotein fraction in adolescent children
Okada, T., Saito, E., Kuromori, Y., Miyashita, M., Iwata, F., Hara, M., & Harada, K. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.030 · Cited by 39
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 39
APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J. F., Almeida, M., Sim, X., Lerner, M. R., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01531-8 · Cited by 40
Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies
Hayashi, T., Hirano, T., Yamamoto, T., Ito, Y., & Adachi, M. (2006) · Metabolism · doi:10.1016/j.metabol.2006.02.014 · Cited by 37
Hypertriglyceridemia and delayed clearance of fat load in transgenic rabbits expressing human apolipoprotein CIII
Ding, Y., Wang, Y., Zhu, H., Fan, J., Yu, L., Liu, C., & Liu, E. (2010) · Transgenic Research · doi:10.1007/s11248-010-9467-5 · Cited by 36
A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II
Meyers, N. L., Larsson, M., Olivecrona, G., & SMALL, D. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629865 · Cited by 34
Parallel increase of plasma apoproteins C‐II and C‐III in Type 2 diabetic patients
Béliard, S., Nogueira, J. P., Maraninchi, M., Lairon, D., Nicolay, A., Giral, P., Portugal, H., Vialettes, B., & Valéro, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02757.x · Cited by 34
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 33
Fibrates and coronary risk reduction
Steiner, G. A. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.04.002 · Cited by 33
Self-citation
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Yang, D., Zhang, J., Xu, J., Zhu, T., Fan, Y., Fan, J., & Chen, Y. E. (2013) · Journal of Visualized Experiments · doi:10.3791/50957 · Cited by 32
Low High-Density Lipoprotein and Risk of Myocardial Infarction
Ramirez, A., & Hu, P. P. (2015) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s26624 · Cited by 31
Association Between Glycemic Control and Morning Blood Pressure Surge With Vascular Endothelial Dysfunction in Type 2 Diabetic Patients
Yoda, K., Inaba, M., Hamamoto, K., Yoda, M., Tsuda, A., Mori, K., Yamada, S., Emoto, M., Koyama, H., & Imanishi, Y. (2013) · Diabetes Care · doi:10.2337/dc13-1102 · Cited by 31
Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 30
Overexpression of apolipoprotein C-III decreases secretion of dietary triglyceride into lymph
Fei, W., Kohan, A. B., Dong, H. H., Yang, Q., Xu, M., Huesman, S., Lou, D., Hui, D. Y., & Tso, P. (2014) · Physiological Reports · doi:10.1002/phy2.247 · Cited by 31
Effects of atorvastatin and n−3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity
Chan, D. C., Nguyen, M. N., Watts, G. F., Ooi, E. M. M., & Barrett, P. H. R. (2010) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28422 · Cited by 29
Determinants of VLDL composition and apo B-containing particles in familial combined hyperlipidemia
Cruz‐Bautista, I., Mehta, R., Cabiedes, J., García-Ulloa, A. C., Guillén-Pineda, L. E., Almeda‐Valdés, P., Ramos, D. C., & Aguilar-Salinas, C. A. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.018 · Cited by 28
The Complex Metabolic Mechanisms Relating Obesity to Hypertriglyceridemia
Eckel, R. H. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.233049 · Cited by 30
Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature
Wölter, M., Röwer, C., Koy, C., Rath, W. H., Pecks, U., & Glocker, M. O. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.04.027 · Cited by 27
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 30
Apolipoprotein CIII Induces Monocyte Chemoattractant Protein-1 and Interleukin 6 Expression Via Toll-Like Receptor 2 Pathway in Mouse Adipocytes: Retracted
Abe, Y., Kawakami, A., Osaka, M., Uematsu, S., Akira, S., Shimokado, K., Sacks, F. M., & Yoshida, M. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.210427 · Cited by 26
Retracted
Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
Sahebkar, A., Simental‐Mendía, L. E., Mikhailidis, D. P., Pirro, M., Banach, M., Sirtori, C. R., Ruscica, M., & Reiner, Ž. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.008 · Cited by 25
Insulin resistance and lipid disorders
Miccoli, R., Keyzer, D. D., Penno, D. G., & Prato, D. S. D. (2008) · Future Lipidology · doi:10.2217/17460875.3.6.651 · Cited by 24
A new multifunctional hydroxytyrosol-fenofibrate with antidiabetic, antihyperlipidemic, antioxidant and antiinflammatory action
Xie, Y., Xu, Y.-H., Chen, Z., Lu, W.-F., Li, N., Wang, Q., Shao, L., Li, Y., Yang, G., & Bian, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.073 · Cited by 23
Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
Sokolov, V. V., Helmlinger, G., Nilsson, C. A. M., Zhudenkov, K., Skrtic, S., Hamrén, B., Peskov, K. V., Hurt‐Camejo, E., & Jansson‐Löfmark, R. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m092486 · Cited by 23

Authors: Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G.
Affiliations: Montreal Clinical Research Institute (CA)
Washington University in St. Louis (US)
Toronto General Hospital (CA)
Corresponding author: Cohn, Jeffrey S.
ORCID: Cohn, Jeffrey S.
Patterson, Bruce W.
Davignon, Jean
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 2004-08
Volume: 89
Issue: 8
Pages: 3949-3955
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jc.2003-032056
OpenAlex: W1994130325
Cited by: 170
References: 58
Citations by year: 2026: 4 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 12 · 2019: 10 · 2018: 5 · 2017: 7 · 2016: 9 · 2015: 10 · 2014: 8 · 2013: 15 · 2012: 9
FWCI: 5.01
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: apolipoprotein C-III, VLDL triglycerides, hypertriglyceridemia, insulin sensitivity, overweight, body mass index, fractional catabolic rate
MeSH terms: Adult, Apolipoproteins C, Body Weight, Humans, Insulin, Insulin Resistance, Kinetics, Lipoproteins, VLDL, Male, Middle Aged, Osmolar Concentration, Triglycerides, Apolipoprotein C-III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks